Amantadine inhibits nicotinic acetylcholine receptor function in hippocampal neurons

Journal of Pharmacology and Experimental Therapeutics

Volumn 281, Issue 2, 1997, Pages 834-844

  Matsubayashi, Hiroaki ^a   Swanson, Karen L ^a   Albuquerque, Edson X ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCHOLINE; AMANTADINE; GLYCINE; ION CHANNEL; KAINIC ACID; N METHYL DEXTRO ASPARTIC ACID; NICOTINIC RECEPTOR;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; FETUS; HIPPOCAMPUS; MEMBRANE CURRENT; MEMBRANE ELECTROPHYSIOLOGY; NONHUMAN; PRIORITY JOURNAL; RAT;

AMANTADINE; ANIMALS; CELLS, CULTURED; HIPPOCAMPUS; NEURONS; NICOTINIC ANTAGONISTS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0030911577     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. ALBUQUERQUE, E. X., COSTA, A. C. S., ALKONDON, M., SHAW, K. P., RAMOA, A. S. AND ARACAVA, Y.: Functional properties of the nicotinic and glutamatergic receptors. J. Recept. Res. 11: 603-625, 1991.
2. ALBUQUERQUE, E. X., ELDEFRAWI, A. T., ELDEFRAWI, M. E., MANSOUR, N. A. AND TSAI, M.-C.: Amantadine: Neuromuscular blockade by suppression of ionic conductance of the acetylcholine receptor. Science (Wash. DC) 199: 788-790, 1978.
3. ALBUQUERQUE, E. X., PEREIRA, E. F. R., BONFANTE-CABARCAS, R., MARCHIORO, M., MATSUBAYASHI, H., ALKONDON, M. AND MAELICKE, A.: Nicotinic acetylcholine receptors on hippocampal neurons: Cell compartment-specific expression and modulatory control of channel activity. Prog. Brain Res. 109: 111-124, 1997.
4. ALBUQUERQUE, E. X., PEREIRA, E. F. R., CASTRO N. G., ALKONDON, M., REINHARDT, S., SCHRÖDER, H. AND MAELICKE, A.: Nicotinic receptor function in the mammalian central nervous system. Ann. N.Y. Acad. Sci. 757: 48-72, 1995a.
5. ALBUQUERQUE, E. X., PEREIRA, E. F. R., CASTRO, N. G. AND ALKONDON, M.: Neuronal nicotinic receptors: Function, modulation and structure. Semin. Neurosci. 7: 91-101, 1995b.
6. ALKONDON, M. AND ALBUQUERQUE, E. X.: Diversity of nicotinic acetylcholine receptors in rat hippocampal neurons. I. Pharmacological and functional evidence for distinct structural subtypes. J. Pharmacol. Exp. Ther. 265: 1455-1473, 1993.
7. ALKONDON, M. AND ALBUQUERQUE, E. X.: Diversity of nicotinic acetylcholine receptors in rat hippocampal neurons. III. Agonist actions of the novel alkaloid epibatidine and analysis of type II current. J. Pharmacol. Exp. Ther. 274: 771-782, 1995.
8. A receptors on hippocampal neurons. J. Pharmacol. Exp. Ther. 279: 1491-1506, 1996a.
9. ALKONDON, M., PEREIRA, E. F. R. AND ALBUQUERQUE, E. X.: Characterization of nicotinic acetylcholine receptors in CA1 neurons of rat hippocampal slices. Soc. Neurosci. Abstr. 22: 1267, 1996b.
10. ALKONDON., M., PEREIRA, E. F. R., WONNACOTT, S. AND ALBUQUERQUE, E. X.: Blockade of nicotinic currents in hippocampal neurons defines methyllycaconitine as a potent and specific receptor antagonist. Mol. Pharmacol. 41: 802-808, 1992.
11. ALKONDON, M., REINHARDT, S., LOBRON, C., HERMSEN, B., MAELICKE, A. AND ALBUQUERQUE, E. X.: Diversity of nicotinic acetylcholine receptors in rat hippocampal neurons. II. The rundown and inward rectification of agonistelicited whole-cell currents and identification of receptor subunits by in ni situ hybridization. J. Pharmacol. Exp. Ther. 271: 494-506, 1994.
12. ARACAVA, Y., DESHPANDE, S. S., SWANSON, K. L., RAPOPORT, H., WONNACOTT, S., LUNT, G. AND ALBUQUERQUE, E. X.: Nicotinic acetylcholine receptors in cultured neurons from the hippocampus and brain stem of the rat characterized by single channel recording. FEBS Lett. 222: 63-70, 1987.
13. BARBOSA, C. T. F., ALKONDON, M., ARACAVA, Y., MAELICKE, A. AND ALBUQUERQUE, E. X.: Ligand-gated channels in acutely dissociated rat hippocampal neurons with long dendrites. Neurosci. Lett. 210: 1-4, 1996.
14. ++.J. Pharmacol. Exp. Ther. 277: 432-444, 1996.
15. CASTRO, N. G. AND ALBUQUERQUE, E. X.: Brief-lifetime, fast-inactivating ion channels account for the α-bungarotoxin-sensitive nicotinic response in hippocampal neurons. Neurosci. Lett. 164: 137-140, 1993.
16. CASTRO, N. G. AND ALBUQUERQUE, E. X.: α-Bungarotoxin-sensitive hippocampal nicotinic receptor channel has a high calcium permeability. Biophys. J. 68: 516-524, 1995.
17. CHEN, H.-S. V., PELLEGRINI, J. W., AGGARWAL, S. K., LEI, A. Z., WARACH, S., JENSEN, F. E. AND LIPTON, S. A.: Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: Therapeutic advantage against NMDA receptor-mediated neurotoxicity. J. Neurosci. 12: 4427-4436, 1992.
18. 125I]αbungarotoxin. J. Neurusci. 5: 1307-1315, 1985.
19. DAVIES, D. L., GRUNERT, R. R., HAFF, R. F., McGAHAN, J. W., NEUMAYER, M., PAULSHOCK, M., WATTS, J. C., WOOD, T. R., HERMANN, E. C. AND HOFFMAN, C. E.: Antiviral activity of 1-adamantanamine (amantadine). Science (Wash. DC) 144: 862-863, 1964.
20. DUFF, K. C., GILCHRIST, P. J., SAXENA, A. M. AND BRAUSHAW, J. P.; Neutron diffraction reveals the site of amantadine blockade in the influenza A M2 ion channel. Virology 202: 287-293, 1994.
21. DUMBILL, L. M. AND ALBUQUERQUE, E. X.: Interaction of amantadine with the nicotinic acetylcholine receptor macromolecule of frog skeletal muscle. Soc. Neurosci. Abstr. 13: 709, 1987.
22. FRANZ, D. N.: Drugs for Parkinson's disease: Centrally acting muscle relaxants. In The Pharmacological Basis of Therapeutics, ed. by L. S. Goodman, A. Gilman, A. G. Gilman and G. B. Koelle, pp. 227-244, 5th edition, Macmillan, New York, 1975.
23. GARCIA-MUNOZ, M., PATINO, P., YOUNG, S. J. AND GROVES, P. M.: Effects of nicotine on dopaminergic nigrostriatal axons requires stimulation of presynaptic glutamatergic receptors. J. Pharmacol. Exp. Ther. 277: 1685-1693, 1996.
24. GRAY, R., RAJAN, A. S., RADCLIFFE, K. A., YAKEHIRO, M. AND DANI, J. A.: Hippocampal synaptic transmission enhanced by low concentrations of nicotine. Nature (Lond.) 383: 713-716, 1996.
25. HAMILL, O. P., MARTY, A., NEHER, E., SAKMANN, B. AND SIGWORTH, F. J.: Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflügers Arch. 391: 85-100, 1981.
26. HITRI, A., CRAFT, R. B., FALLON, J., SETHI, R. AND SINHA, D.: Serum neuroleptic and anticholinergic activity in relationship to cognitive toxicity of antiparkinsonian agents in schizophrenic patients. Psychopharmacol. Bull. 23: 33-37, 1987.
27. ISHIHARA, K., ALKONDON, M., MONTES, J. G. AND ALBUQUERQUE, E. X.: Nicotinic responses in acutely dissociated rat hippocampal neurons and the selective blockade of fast-desensitizing nicotinic currents by lead. J. Pharmacol. Exp. Ther. 273: 1471-1482, 1995.
28. JACKISCH, R., LINK, T., NEUFANG, B. AND KOCH, R.: Studies on the mechanism of action of the antiparkinsonian drugs memantine and amantadine: No evidence for direct dopaminomimetic or antimuscarinic properties. Arch. Int. Pharmacodyn. Ther. 320: 21-42, 1992.
29. KORNHUBER, J., QUACK, G., DANYSZ, W., JELLINGER, K., DANIELCZYK, W., GSELL, W. AND REIDERER, P.: Therapeutic brain concentration of the NMDA receptor antagonist amantadine. Neuropharmacology 34: 713-721, 1995.
30. LINDSTROM, J.: Nicotinic acetylcholine receptors. In Ligand-and Voltage-Gated Ion Channels, ed. by R. A. North, pp. 153-175, CRC Press, Boca Raton, 1995.
31. LUPP, A., LUCKING, C. H., KOCH, R., JACKISCH, R. AND FEUERSTEIN, T. J.: Inhibitory effects of the antiparkinsonian drugs memantine and amantadine on N-methyl-D-aspartate-evoked acetylcholine release in the rabbit caudate nucleus in vitro. J. Pharmacol. Exp. Ther. 263: 717-724, 1992.
32. MATSUBAYASHI, H. AND ALBUQUERQUE, E. X.: Inhibitory effects of the antiviral agent amantadine on nicotinic acetylcholine responses in rat hippocampal cultured neurons. Soc. Neurosci. Abstr. 21: 1834, 1995.
33. MCEVOY, J. P.: A double-blind crossover comparison of antiparkinson drug therapy: Amantadine versus anticholinergics in 90 normal volunteers, with an emphasis on differential effects on memory function. J. Clin. Psychiatry 48: 20-23, 1987.
34. PALMA, E., BERTRAND, S., BINZONI, T. AND BERTRAND, D.: Neuronal nicotinic α7 receptor expressed in Xenopus oocytes presents five putative binding sites for methyllycaconitine. J. Physiol. (Lond.) 491: 151-161, 1996.
35. PARSONS, C. G., WUACK, G., BRESINK, I., BARAN, L., PRZEGALINSKI, E., KOSTOSWSKI, W., KRAZASCIK, P., HARMANN, S. AND DANYSZ, W.: Comparison of potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology 34: 1239-1258, 1995.
36. PEREIRA, E. F. R., ALKONDON, M., MCINTOSH, J. M. AND ALBUQUERQUE, E. X.: α-Conotoxin IMI, a competitive antagonist of the neuronal nicotinic acetylcholine receptor in hippocampal neurons. J. Pharmacol. Exp. Ther. 278: 1472-1483, 1996.
37. PEREIRA, E. F. R., REINHARDT-MAELICKE, S., SCHRATTENHOLZ, A., MAELICKE, A. AND ALBUQUERQUE, E. X.: Identification and functional characterization of a new agonist site on nicotinic acetylcholine receptors of cultured hippocampal neurons. J. Pharmacol. Exp. Ther. 265: 1474-1491, 1993.
38. 3H]dopamine release from striatal synaptosomes: Pharmacological characterisation. J. Neurochem. 54: 937-945, 1990.
39. SARGENT, P. B.: The diversity of neuronal acetylcholine receptors. Annu. Rev. Neurosci. 16: 403-443, 1993.
40. SCHRATTENHOLZ, A., COBAN, T., SCHRODER, B., OKONJO, K. O., KUHLMANN, J., PEREIRA, E. F. R., ALBUQUERQUE, E. X. AND MAELICKE, A.: Biochemical characterization of a novel channel-activating site on nicotinic acetylcholine receptors. J. Recept. Res. 13: 393-412, 1993.
41. SCHWAB, R. S., POSKANZER, D. C., ENGLAND, A. C., JR. AND YOUNG, R. R.: Amantadine in Parkinson's disease: Review of more than two years' experience. J. Am. Med. Assoc. 222: 792-795, 1972.
42. SÉGUÉLA. P., WADICHE, J., DINELEY-MILLER, K., DANI, J. A. AND PATRICK, J. W.: Molecular cloning, functional properties and distribution of rat brain α7: A nicotinic cation channel highly permeable to calcium. J. Neurosci. 13: 596-604, 1993.
43. SHAHAR, E. M. AND BRAND, N.: Effect of add-on amantadine therapy for refractory absence epilepsy. J. Pediatr. 121: 819-821, 1992.
44. SHAW, K.-P., ARACAVA, Y., AKAIKE, A., DALY, J. W., RICKKTT, D. L. AND ALBUQUERQUE, E. X.: The reversible cholinesterase inhibitor physostigmine has channel-blocking and agonist effects on the acetylcholine receptor-ion channel complex. Mol. Pharmacol. 28: 527-538, 1985.
45. STANDAERT, D. G. AND YOUNG, A. B.: Treatment of central nervous system degenerative disorders. In Goodman & Gilman's The Pharmacological Basis Therapeutics, ed. by J. G. Hardman, L. E. Limbird, P. B. Molinuff, R. W. Ruddon and A. G. Gilman, pp. 503-519, 9th edition, McGraw-Hill New York, 1996.
46. STOOF, J. C., BOOIJ, J., DRUKARCH, B. AND WOLTERS, E. C.: The anti-parkinsonian drug amantadine inhibits the N-methyl-D-aspartic acid-evoked release of acetylcholine from rat neostriatum in a non-competitive way. Eur. J. Pharmacol. 213: 439-443, 1992.
47. TSAI, M.-C., MANSOUR, N. A., ELDEFRAWI, A. T., ELDEFRAWI, M. E. AND ALBUQUERQUE, E. X.: Mechanism of action of amantadine on neuromuscular transmission. Mol. Pharmacol. 14: 787-803, 1978.
48. UNWIN, N.: Acetylcholine receptor channel imaged in the open state. Nature (Lond.) 373: 37-43, 1995.
49. VAN PUTTEN, T., GELENBERG, A. J., LAVORI, P. W., FALK, W. E., MARDER, S. R., SPRING, B., MOHS, R. C. AND BROTMAN, A. W.: Anticholinergic effects on mory: Benztropine us. amantadine. Psychopharmacol. Bull. 23: 26-29, 1987.
50. WANG, C., LAMB, R. A. AND PINTO, L. H.: Direct measurement of the influenza A virus M2 protein ion channel activity in mammalian cells. Virology 205: 133-140, 1994.
51. WARNICK, J. E., MALEQUE, M. A., BAKRY, N., ELDEFRAWI, A. T. AND ALBUQUERQUE, E. X.: Structure-activity relationships of amantadine. I. Interaction of the N-alkyl analogues with the ionic channels of the nicotinic acetylcholine receptor and electrically excitable membrane. Mol. Pharmacol. 22: 82-93,1982